Hepatitis C disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NANBH MCID: HPT001 MIFTS: 70	Hepatitis C (NANBH) Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Name: Hepatitis C ¹² ⁷⁶ ⁵⁵ ⁴³ ⁴⁴ ¹⁵ ⁷³

Hepatitis C Infection ¹² ¹⁵

Hepatitis C, Chronic ⁷³

Chronic Hepatitis C ¹²

Hepatitis Nona Nonb ¹²

Hepatitis C Chronic ⁵⁵

Viral Hepatitis C ¹²

Nanbh ¹²

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Liver diseases Endocrine diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1883

ICD10 ³³ B19.2 B19.20

ICD9CM ³⁵ 070.7

MeSH ⁴⁴ D006526

NCIt ⁵⁰ C3098

SNOMED-CT ⁶⁸ 50711007

UMLS ⁷³ C0019196 C0524910

Sources

Summaries for Hepatitis C

MedlinePlus : ⁴³ Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis C, is caused by the hepatitis C virus (HCV). It usually spreads through contact with infected blood. It can also spread through sex with an infected person and from mother to baby during childbirth. Most people who are infected with hepatitis C don't have any symptoms for years. If you do get symptoms, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. A blood test can tell if you have it. Usually, hepatitis C does not get better by itself. The infection can last a lifetime and may lead to cirrhosis (scarring of the liver) or liver cancer. Medicines sometimes help, but side effects can be a problem. Serious cases may need a liver transplant. There is no vaccine for HCV. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis C, also known as hepatitis c infection, is related to hepatitis c virus and hepatitis, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis C is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Intron A and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotype is immune system.

Disease Ontology : ¹² A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis C virus, which is transmitted by blood from an infected person enters the body of an uninfected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : ⁷⁶ Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the... more...

Sources

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Hepatitis C Virus	Autoimmune Hepatitis
Hepatitis B	Hepatitis a
Hepatitis C	Viral Hepatitis
Hepatitis D	Hepatitis E

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 696)

#	Related Disease	Score	Top Affiliating Genes
1	hepatitis c virus	33.9	CD81 CLDN1 CLDN6 DDX58 GPT IFNG
2	hepatitis	32.5	CD81 CLDN1 CLDN6 DDX58 GPT IFNA1
3	hepatitis b	31.4	GPT IFNA1 IFNA2 IFNG
4	cryoglobulinemia, familial mixed	31.4	IFNA1 IFNA2
5	viral infectious disease	31.3	CD81 DDX58 GPT IFNA1 IFNA2 IFNAR1
6	noonan syndrome 3	31.2	CD81 DDX58 IFNA1 IFNB1 IRF3 MAVS
7	viral hepatitis	31.2	GPT IFNA1 IFNA2 KRT18
8	liver cirrhosis	31.0	GPT HOTAIR IFNA1 KRT18
9	noonan syndrome 2	30.9	CD81 DDX58 IRF3 MAVS
10	hepatitis a	30.6	GPT IFNG MAVS
11	acquired immunodeficiency syndrome	30.3	IFNA1 IFNA2 IFNG
12	hepatitis e	30.2	GPT IFNG TLR3
13	oral erosive lichen	30.2	IFNA1 IFNB1
14	stomatitis	30.1	DDX58 IFNA2 LDLR
15	severe acute respiratory syndrome	30.0	IFNA1 IFNB1 IFNG IRF3
16	west nile virus	29.9	DDX58 IFNA1 IRF3 TLR3
17	kaposi sarcoma	29.9	IFNA1 IFNA2 IFNB1 IRF3
18	encephalitis	29.8	DDX58 IRF3 TLR3
19	influenza	29.8	DDX58 IFNA1 IFNB1 IFNG IRF3 TLR3
20	japanese encephalitis	29.8	DDX58 IFNB1 TLR3
21	renal cell carcinoma, nonpapillary	29.7	HOTAIR IFNA1 IFNA2 IFNG
22	herpes simplex	29.7	DDX58 IFNA1 IFNB1 IRF3 TLR3
23	variola major	29.6	IFNG TLR3
24	measles	29.4	DDX58 IFNA1 IFNB1 IFNG TLR3
25	chronic end-stage hepatitis c	12.2
26	recurrent hepatitis c virus induced liver disease in liver transplant recipients	12.1
27	hepatocellular carcinoma	11.6
28	liver disease	11.5
29	porphyria cutanea tarda	11.4
30	fatty liver disease	11.4
31	polyarteritis nodosa	11.4
32	fibrillary glomerulonephritis	11.4
33	opiate dependence	11.4
34	linear lichen planus	11.3
35	immunotactoid glomerulopathy	11.3
36	heroin dependence	11.3
37	immunotactoid or fibrillary glomerulopathy	11.3
38	pars planitis	11.0
39	intermediate uveitis	11.0
40	papular mucinosis	11.0
41	cryoglobulinemia	10.8
42	glomerulonephritis	10.6
43	lymphoma	10.6
44	porphyria	10.5
45	vasculitis	10.5
46	membranoproliferative glomerulonephritis	10.4
47	lichen planus	10.4
48	fatty liver disease, nonalcoholic 1	10.3
49	thalassemia	10.3
50	oral lichen planus	10.3

Graphical network of the top 20 diseases related to Hepatitis C:

Sources

Symptoms & Phenotypes for Hepatitis C

Symptoms:

¹²

• fever
• vomiting
• fatigue
• abdominal pain
• jaundice

• nausea
• joint pain
• loss of appetite
• clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis C:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.32	CD81 DDX58 IFNAR1 IFNB1 IFNG IRF3

Sources

Drugs & Therapeutics for Hepatitis C

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Intron A ¹⁸ ⁴⁹	INTERFERON ALFA-2B	Schering-Plough	December 1997/ December 1995/ March 1997
FDA Label: Intron A Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C Indications and Usage: ¹⁸ Hairy Cell Leukemia INTRONÂ® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOLÂ® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS). DrugBank Targets: ¹⁶ 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1 Mechanism of Action: ¹⁸ Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production Action: stimulation, induction (unspecified effects on oncogene expression) FDA: -

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 606)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

22916-47-8

4189

Tacrolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

104987-11-3

445643 439492

Ezetimibe

Approved

Phase 4,Phase 2,Phase 1

163222-33-1

150311

Ribavirin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

36791-04-5

37542

Peginterferon alfa-2a

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

198153-51-4

5360545

Acarbose

Approved, Investigational

Phase 4

56180-94-0

441184

Peginterferon alfa-2b

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

99210-65-8, 215647-85-1

Pioglitazone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

111025-46-8

4829

Metformin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

657-24-9

14219 4091

leucovorin

Approved

Phase 4,Phase 2,Phase 1

58-05-9

6006 143

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

93-14-1

3516

Methadone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

76-99-3

4095

Ritonavir

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

155213-67-5

392622

Emtricitabine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

143491-57-0

60877

Dopamine

Approved

Phase 4,Phase 3,Phase 2

51-61-6, 62-31-7

681

Amantadine

Approved

Phase 4,Phase 3,Phase 2

768-94-5

2130

Nitazoxanide

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

55981-09-4

41684

Sofosbuvir

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

1190307-88-0

45375808

Ledipasvir

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1256388-51-8

67505836

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Entecavir

Approved, Investigational

Phase 4,Phase 2,Phase 3

142217-69-4

153941

Insulin Glargine

Approved

Phase 4

160337-95-1

Insulin glulisine

Approved

Phase 4

207748-29-6

Zinc

Approved, Investigational

Phase 4,Not Applicable

7440-66-6

Simeprevir

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

923604-59-5

66576988

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

94-09-7, 1994-09-7

2337

tannic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2

53123-88-9

46835353 6436030 5284616

Prednisone

Approved, Vet_approved

Phase 4,Phase 2

53-03-2

5865

Mycophenolic acid

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

24280-93-1

446541

Everolimus

Approved

Phase 4,Phase 3,Phase 2

159351-69-6

6442177

Efavirenz

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

154598-52-4

64139

Zidovudine

Approved

Phase 4,Phase 1,Phase 2

30516-87-1

35370

Lamivudine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

134678-17-4

60825

Interferon alfacon-1

Approved, Investigational

Phase 4,Phase 3,Phase 2

118390-30-0

9554198

Lopinavir

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

192725-17-0

92727

Basiliximab

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

152923-56-3, 179045-86-4

Nevirapine

Approved

Phase 4

129618-40-2

4463

Rifaximin

Approved, Investigational

Phase 4,Phase 2,Not Applicable

80621-81-4

6436173

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 2

124-94-7

31307

Angiotensin II

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

11128-99-7, 68521-88-0, 4474-91-3

172198 65143

Losartan

Approved

Phase 4

114798-26-4

3961

Iron

Approved

Phase 4,Phase 2,Not Applicable

7439-89-6

23925

Orlistat

Approved, Investigational

Phase 4,Not Applicable

96829-58-2

3034010

Citalopram

Approved

Phase 4,Phase 3,Phase 2,Phase 1

59729-33-8

2771

Cobicistat

Approved

Phase 4,Phase 3,Phase 1

1004316-88-4

Nelfinavir

Approved

Phase 4

159989-64-7

64143

Rosiglitazone

Approved, Investigational

Phase 4

122320-73-4

77999

Ethanol

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

64-17-5

702

Maraviroc

Approved, Investigational

Phase 4,Phase 3,Phase 1

376348-65-1

3002977

Interventional clinical trials:

(show top 50) (show all 2345)

#	Name	Status	NCT ID	Phase	Drugs
1	Hepatitis C in Renal Transplant Recipients	Unknown status	NCT02108301	Phase 4	tacrolimus-cyclosporine A
2	Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)	Unknown status	NCT02745132	Phase 4
3	Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	Unknown status	NCT02768545	Phase 4	Ezetimibe
4	Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C	Unknown status	NCT01649245	Phase 4	Reiferon retard
5	Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients	Unknown status	NCT01439776	Phase 4
6	Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels	Unknown status	NCT00575627	Phase 4	Peg-Interferon alpha2a plus Ribavirin
7	Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C	Unknown status	NCT02639585	Phase 4	Daclinza and Sunvepra
8	The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin	Unknown status	NCT01025765	Phase 4	Pioglitazone;Acarbose;Metformin
9	A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.	Unknown status	NCT02150291	Phase 4	Neurobion;placebo
10	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma	Unknown status	NCT00834860	Phase 4	peginterferon alpha-2a and ribavirin
11	Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users	Unknown status	NCT01105611	Phase 4	Raltegravir;Atazanavir/Ritonavir
12	Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)	Unknown status	NCT00127777	Phase 4	Amantadine sulphate (in addition to standard treatment)
13	PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)	Unknown status	NCT01056172	Phase 4	Peginterferon alfa-2a and Ribavirin;Peginterferon alfa-2a and Ribavirin
14	Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population	Unknown status	NCT01896609	Phase 4	Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
15	Nutritional Support During Antiviral Therapy for Hepatitis C	Unknown status	NCT00841243	Phase 4
16	Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy	Unknown status	NCT02638233	Phase 4	Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
17	Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV	Unknown status	NCT00611819	Phase 4	Peg interferon + Ribavirin;Peg interferon + Ribavirin
18	Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients	Unknown status	NCT02008214	Phase 4	Pentoxifylline;Placebo
19	A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)	Unknown status	NCT01731301	Phase 4	Ribavirin;Peginterferon;Boceprevir
20	Telaprevir in Genotype 3 HCV	Unknown status	NCT02087111	Phase 4	Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
21	Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies	Unknown status	NCT00887081	Phase 4	PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
22	Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents.	Unknown status	NCT02802280	Phase 4
23	Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	Unknown status	NCT00370617	Phase 4	metformin
24	36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8	Unknown status	NCT01683786	Phase 4	Pegintron + Riba
25	Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients	Unknown status	NCT00526448	Phase 4	ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
26	Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium	Unknown status	NCT01783314	Phase 4
27	MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV	Unknown status	NCT03003338	Phase 4	OBV/PTV/r and DSV;Placebo to match OBV/PTV/r and DSV
28	Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease	Unknown status	NCT02691728	Phase 4	LDV/SOF FDC
29	Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B	Unknown status	NCT00597259	Phase 4	Pegasys plus Entecavir;Entecavir
30	Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B	Unknown status	NCT01925820	Phase 4	Pegasys&Entecavir
31	Improved Prevention of Perinatal Hepatitis B Transmission	Unknown status	NCT01133184	Phase 4
32	Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial	Unknown status	NCT01143948	Phase 4	Glargine & Glulisine;Regular insulin;NPH & regular insulin
33	Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)	Completed	NCT02624063	Phase 4	Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
34	Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)	Completed	NCT02768961	Phase 4	sofosbuvir;ledipasvir
35	Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation	Completed	NCT00821587	Phase 4	Cyclosporine;Tacrolimus
36	The SIM-SOF Trial for Hepatitis C	Completed	NCT02168361	Phase 4	Pegylated Interferon alfa-2b;Simeprevir;Ribavirin;Sofosbuvir
37	Australian Trial in Acute Hepatitis C	Completed	NCT00192569	Phase 4	Pegylated Interferon alfa 2a;Ribavirin (HIV conifected patients only)
38	Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World	Completed	NCT02964091	Phase 4	sofosbuvir/ledipasvir
39	Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease	Completed	NCT00028093	Phase 4	Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
40	Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C	Completed	NCT00938860	Phase 4	cyclosporin (Neoral);tacrolimus (Prograf)
41	Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C	Completed	NCT00917358	Phase 4	Pegylated interferon alfa-2a
42	A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3	Completed	NCT01258101	Phase 4	peginterferon alfa-2a [Pegasys];peginterferon alfa-2a [Pegasys];ribavirin;ribavirin
43	Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy	Completed	NCT01045278	Phase 4	Pegylated interferon-alfa-2b and ribavirin
44	Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients	Completed	NCT01469884	Phase 4	Everolimus;Cyclosporine;Tacrolimus
45	A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C	Completed	NCT01675427	Phase 4
46	Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C	Completed	NCT00948220	Phase 4	peginterferon alfa-2a and ribavirin
47	Treatment of Recently Acquired Hepatitis C Virus Infection	Completed	NCT01336010	Phase 4	Peginterferon alfa-2a;Ribavirin
48	Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)	Completed	NCT01134952	Phase 4	Mycophenolate to sirolimus switch
49	A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment	Completed	NCT03212521	Phase 4	glecaprevir/pibrentasvir
50	Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection	Completed	NCT02377856	Phase 4	pegylated interferon alpha 2a, ribavirin

Search NIH Clinical Center for Hepatitis C

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

boceprevir

daclatasvir

dasabuvir

elbasvir

grazoprevir

hepatitis c virus non-nucleoside ns5b palm polymerase inhibitor [epc]

hepatitis c virus ns3/4a protease inhibitor [epc]

hepatitis c virus ns5a inhibitor [epc]

hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc]

interferon alfa-2a

interferon alfa-2b

interferon alfa-3n,human leukocyte derived

interferon alfacon-1

interferon gamma-1b

interferons

ledipasvir

ombitasvir

paritaprevir

peginterferon

peginterferon alfa-2a

peginterferon alfa-2b

recombinant interferon beta-1a

recombinant interferon beta-1b

ribavirin

simeprevir

sofosbuvir

telaprevir

velpatasvir

Cochrane evidence based reviews: hepatitis c

Sources

Genetic Tests for Hepatitis C

Sources

Anatomical Context for Hepatitis C

MalaCards organs/tissues related to Hepatitis C:

⁴¹

Liver, Testes, Kidney, T Cells, B Cells, Thyroid, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

¹⁹

Liver

Sources

Publications for Hepatitis C

Articles related to Hepatitis C:

(show top 50) (show all 10660)

#	Title	Authors	Year
1	Editorial: comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C. ( 30548317 )	Kawabe N...Yoshioka K	2019
2	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C - authors' reply. ( 30548320 )	Liu CH...Kao JH	2019
3	Pharmacy-led hepatitis C treatment pathways to help ensure elimination. ( 30527577 )	Gunn J...Higgs P	2019
4	Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village. ( 30527578 )	Shiha G...Easterbrook P	2019
5	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. ( 30527582 )	Torres MCP...Aghemo A	2019
6	Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. ( 30467877 )	Nguyen E...Nguyen MH	2019
7	Strategies for access to affordable hepatitis C testing and treatment in Asia. ( 30480583 )	Khwairakpam G...Burry J	2019
8	HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region. ( 30489347 )	Mehdiyev R...Gurbanova E	2019
9	The Revolution in Treatment of Hepatitis C. ( 30466675 )	Mayberry J...Lee WM	2019
10	TLR3 and TLR4 SNP variants in the liver disease resulting from hepatitis B virus and hepatitis C virus infection. ( 30421643 )	Sghaier I...Loueslati BY	2019
11	Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. ( 30401643 )	Sharafi H...Alavian SM	2019
12	Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. ( 30239347 )	Attia D...Potthoff A	2019
13	Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. ( 30247174 )	Essa M...Salama M	2019
14	Circulating microRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients. ( 30133717 )	El-Hefny M...Abdel Wahab AH	2019
15	Human pegivirus isolates characterized by deep sequencing from hepatitis C virus-RNA and human immunodeficiency virus-RNA-positive blood donations, France. ( 30133782 )	Jordier F...Biagini P	2019
16	No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. ( 30142097 )	Mun EJ...Ioannou GN	2019
17	Skeletal muscle mass depletion in patients with hepatitis C virus infection. ( 30179904 )	Fukui A...Yoshioka K	2019
18	Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients. ( 30199473 )	Abdelaziz AO...Elbaz TM	2019
19	Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay. ( 30091789 )	Lu T...Li J	2019
20	Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. ( 30024489 )	Elhelbawy M...Waked I	2019
21	Design and Development of Modified mRNA Encoding Core Antigen of Hepatitis C Virus: a Possible Application in Vaccine Production ( 30056690 )	Sharifnia Z...Zarghami N	2019
22	Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )	Bielen R....Lazarus J.V.	2018
23	Hepatitis C virus infection in children in the era of direct-acting antiviral. ( 29962813 )	Pawlowska M....Domagalski K.	2018
24	Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population. ( 29429421 )	Fill M.A....Wester C.	2018
25	An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )	El Kassas M....Esmat G.	2018
26	Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. ( 29972246 )	Gowda C....Honegger J.R.	2018
27	Hepatitis C screening in patients with oral lichen planus. ( 29971956 )	Karimi-Sari H....Alavian S.M.	2018
28	Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. ( 29248968 )	Ishibashi M....Esumi M.	2018
29	Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. ( 29235977 )	Li Z....Liu Q.	2018
30	Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV. ( 29438195 )	Pradat P....Cotte L.	2018
31	Hepatitis C virus infection and risk of osteoporotic fracture: A systematic review and meta-analysis. ( 29322660 )	Wijarnpreecha K....Ungprasert P.	2018
32	Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )	Wyles D.L....Peters M.G.	2018
33	Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )	Abd Alla M.D.A....Galal A.G.M.	2018
34	Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with I^-Thalassemia Major. ( 29743790 )	Mehta R....Parekh V.	2018
35	HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015. ( 29981093 )	Courtemanche Y....Alary M.	2018
36	Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. ( 29962673 )	Prasad N....Gupta A.	2018
37	Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. ( 29443378 )	Kwon Y.C....Ray R.	2018
38	Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. ( 29446443 )	Shan Z....Rong X.	2018
39	Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection. ( 29974665 )	Younossi Z.M....Wei L.	2018
40	Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. ( 29399747 )	Zhu D.Y....Ding W.L.	2018
41	Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients. ( 29290175 )	Calabrese M.J....Shaya F.T.	2018
42	Psychiatric and functional neuroimaging abnormalities in chronic hepatitis C virus patients: Is vasculitis a contributing factor? ( 29935864 )	Zayed H.S....Nawito Z.	2018
43	Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )	Andrade X.A....Singh A.	2018
44	Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. ( 29438397 )	Kelly M.L....Post J.J.	2018
45	Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. ( 29557805 )	Tahir M....Charles L.	2018
46	Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. ( 29271782 )	Roulot D....Serfaty L.	2018
47	Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. ( 29975243 )	Hill L.A....Cachay E.	2018
48	microRNA-122 amplifies hepatitis C virus translation by shaping the structure of the internal ribosomal entry site. ( 29973597 )	Schult P....Lohmann V.	2018
49	Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. ( 29022122 )	Nguyen L.T....Nguyen L.A.	2018
50	Cerebral Malaria in a Patient with HIV, Hepatitis B, and Hepatitis C. ( 29974024 )	Uddin S.M.M....Kazmi S.F.A.	2018

Sources

Genes for Hepatitis C

Genes related to Hepatitis C (1 elite genes):

(show all 36)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MIR122	MicroRNA 122	RNA Gene	358.09	Causal ⁴⁷ GeneCards inferred via : Publications (show sections)	19122656
2	NRIR	Negative Regulator Of Interferon Response	RNA Gene	154.21	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25122750
3	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁹	27129296
4	SCARB1	Scavenger Receptor Class B Member 1	Protein Coding	66.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Summaries Proteins Pathways & Interactions Functions (show sections)	19828610 15998599 19087225 (more) 19094442 17507483 16725222 19776133 18216094
5	CD81	CD81 Molecule	Protein Coding	61.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	11130883 16735696 16623441 (more) 11391542 17194487 11985527 15230853 12645944 14722300 19489072 11024134 11134943 10400713 18474223 16943299 12210407 17177963 11169450 19626614 20004001 12525620 11115611 11044085 19574424 12492902 19828092 19321602 16628670 16162201 12708969 19941400 19776133 15611113 15368299 14966136 12732424 18337570 17507469 16725222 12437138 12421929 19476617 16339892 17500230 11602742 9794763 16641285 12713876
6	IFNA2	Interferon Alpha 2	Protein Coding	58.63	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	7890902 1323873 8872767 (more) 11391241 16696859 7493304 1646369 9438325 19440994 17875005 16371151 7890900 16108761 7827383 1957127 18067041 8188164 8569947 9402109 9429212 9893388 10460040 11213071 11346153 14568274 16792540 16761995 16885125 17133585 18498412 18568137 18925643 19291011 15785092 15357651 15188249 10529547 9310930 8738737 7784752 7749499 1521895 16314819 16539640 15844708 14687168 14624375 12206880 9848789 9840131 9756471 7525694 8283800 8244259 19403391 19177439 18672529 17680654 16940889 12854039 12644153 10522017 7636506 7982638 12500209 10944819 10535477 9493514 9185775 8868074 7781437 7532917 12679925 7890893 7927216 7918078 7506225 7685368 19344193 17631045 17408662 8811643 7600144 20104263 19891686 19043919 17570576 17433090 17297412 19898214 19277451 17105597 17004124 16761996 16926548 15683421 15148560 12702987 10721171 9382363 18020586 11772139 9563925 18383998 15233669 7984968 15208476 9439491 8384978 9448171 8774972 8757098 7516951 8200260 7506223 8384732 1300264 15543388 14625812 9493517 9187562 8864684 8632622 7623006 7694894 18219972 15499417 11827565 9395758 19084937 17244248 12578794 9112292 8898424 8792690 7493300 8036685 17600286 16234288 15642681 15902734 15118982 11984144 11246613 20524482 18416586 17825059 18081733 10673309 9795916 8855738 8592590 12945009 11684934 11529376 11399913 12627987 9873862 17163300 15906777 15362767 12618532 12499179 12297606 9951914 16459223 17881538 11474319 8138252 9696488 9860407 10971823 1904507 19493343 19084938 17511042 16531110 12749244 11915769 16964669 16773695 16521701 15990928 15681898 15571424 15286876 14984381 12645805 14633181 12970155 11432797
7	IFNA1	Interferon Alpha 1	Protein Coding	50.48	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	9136611 9348307 9363321 (more) 11068424 9881484 16761995 7875660 15578378 17148690 12796597 8021761 9013095 19853722 16907848 1279945 10831463 9459633 17682992 10213463 16394599 11503033 7542385 10886533 9384338 7564784 19855041 16001668 15853986 12389150 11262201 9458323 20149251 17600290 16496056 15505982 12395337 7770957 20235331 16732861 16498048 16462544 16437637 15060764 17845538 15767792 15485018 10921417 9581673 8528942 17589934 16557537 12601359 11693335 9734490 8742914 7920883 14583865 11443537 11146898 9639122 9099919 17030563 11798458 11335880 11197246 10830239 10718942 7740291 7647904 8539489 8713702 8836892 9458322 9584572 9731893 11496031 11200421 11099068 10890323 10797610 10629594 10419923 10406179 9894629 15626155 15107924 14988824 14733608 14642620 14603150 14552746 12832744 12684917 17593231 17708618 17696240 17451199 17223968 17133546 10846411 9751011 15313671 12639294 8834873 10967910 14980101 11606177 8808431 7529222 9794931 12632506 10347136 15785091 9440624 9475663 7924750 11454179 10534358 9831409 8918079 7521413 19687584 18184190 17441804 16299717 12875732 11003631 9181527 7493303 7521419 15626156 14720084 14704637 14567556 15647837 12211720 11675141 11399913 10607247 9581698 9391306 9389973 10921396 19709362 16166794 15756146 12753340 11454180 8639763 7521308 10406176 9471022 18329125 17164553 12468961 11915044 11015548 10094956 9604792 11794896 8033418 7521420 8805853 9181530 9076626 11230751 11494552 18019713 16407785 16235981 16201891 16108765 15868370 12187585 11993412 11528252 17625432 17573947 17197556 16433196 14688060 14988669 9831362 9537454 9384479 8768457 7515124 7686526 18370481 17823081 18066038 11283865 11207901 10755692 10733558
7	IFNA1::MIR122 ⁴⁷	MIR122 Macro RNA (hsa-miR-122) targets IFNA1
8	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	49.56	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Functions (show sections)	12870728 8243482 11426070 (more) 16460486 9535253 10553026 15801921 16146553 7940658 17297429 12389938 11148444 7790700 19350657 1647082 7509301 8310483 7542359 8743227 11680575 12524415 7865717 7505292 1323873 1657545 18370481 17327945 16842319 15970184 15369508 12623510 10397080 9570237 9218853 8583136 1651830 19360373 18174875 16038760 12743782 11684554 11422630 11115049 10534514 8943974 8938557 8549952 7593117 12412994 11350550 10447418 10212707 10574619 9789966 9639122 8868074 8712840 9252161 7493303 7572160 7542854 7608477 7930476 7508972 19789166 18841029 11054390 10745231 10607246 9703524 18814233 17971091 17014573 17153452 16930357 14587305 12649165 12422335 8740843 8061799 1681620 1909848 19669268 16821591 16394797 14571787 7519895 19651008 17593075 17591076 15387343 15175944 14760885 12883496 12505820 11926856 11572574 11272796 10342322 16487620 15921043 10773739 9641644 12423276 7593464 10959807 11669085 10894594 11007237 11192321 9493517 9328332 8808445 20002296 16509866 16254522 15740537 16645500 15850472 15626156 15185315 15016922 12297846 11580150 10413866 10625321 8727711 8601375 7540996 8020662 8049886 1330930 18329125 16886160 11684312 12630015 10029282 9257242 8745594 19890604 19521923 17827956 20455406 19669312 18029322 12705485 14582461 12794722 12452844 10824882 10361518 10086636 9438325 9041004 11432516 10511883 7685731 1330798 20163376 20071593 9305668 16245074 15080567 12845983 12164963 11285561 11124852 10920503 9633204 14571765 15598087
9	KRT18	Keratin 18	Protein Coding	47.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Proteins Variants (show sections)	20334631 15850472 20374042 (more) 18329127 19333204 19881359
10	IFNG	Interferon Gamma	Protein Coding	47.49	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Variants (show sections)	10648463 18384906 11236507 (more) 14593531 14624379 19450146 10996386 7557851 10938594 11870386 12438568 10960455 12692291 16472599 18184198 17784818 17147054 15977245 15078471 11995406 11851899 10823750 20038212 12717401 12297850 11702012 9096578 15958073 12938195 10866531 19773191 19480854 20209325 17175001 17348823 16637863 11498684 9245544 9041343 18292209 16543291 17229698 16938650 16241862 15368525 14690454 11391238 20005287 18453613 17882815 16227262 8395442 20203164 18646554 17624844 15488246 12021342 16232225 17148690 18695347 19918044 11380795 15913831 10644322 11694847 1341444 14733779 12794718 8978359 10798608 19469176 12663233 16051377 19172906 18689269 12816762 9458493 8482853 10604568 17199111 11298134 10570316 9452789 7956620 19200135 18775023 18372599 16408623 16234066 11690712 10930306 16765635 15057302 11712433 8855173 1899852 18341617 11506737 8884741 16764700 16425360 18216180
11	IFNB1	Interferon Beta 1	Protein Coding	47.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	11211884 15488246 20173023 (more) 18508652 8652925 16585524 7493297 14691655 15575242 11032403 12468961 15561229 17804510 10450805 17517627 17661838 12680611 19329508 9041468 9058311 12230024 11824799 10080158 19262055 19092269 12391678 17654600 16060397 7572160 16522372 10347136 20479896
12	DDX58	DExD/H-Box Helicase 58	Protein Coding	46.71	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	16116171 16585524 20034464 (more) 17517627
13	CLDN1	Claudin 1	Protein Coding	45.5	GeneCards inferred via : Publications Proteins Pathways & Interactions Functions (show sections)
14	IFNL4	Interferon Lambda 4 (Gene/Pseudogene)	Protein Coding	45.26	GeneCards inferred via : Publications Summaries Proteins Functions (show sections)
15	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	44.74	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Proteins Pathways & Interactions (show sections)	16585524 17517627
16	IRF3	Interferon Regulatory Factor 3	Protein Coding	44.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	18203148 17668876 19625408 (more) 15709037 17651439
17	CLDN6	Claudin 6	Protein Coding	44.45	GeneCards inferred via : Publications Summaries Pathways & Interactions Functions (show sections)
18	LDLR	Low Density Lipoprotein Receptor	Protein Coding	43.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	17473053 16927291 11208419 (more) 16871569 16991080 19489072 11024134 17156886 19941400
19	IFNAR1	Interferon Alpha And Beta Receptor Subunit 1	Protein Coding	43.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	15990456 9563926 15107924 (more) 17823081 12141824
20	TLR3	Toll Like Receptor 3	Protein Coding	43.13	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	19625408 18021446 19475618
21	IFNAR2	Interferon Alpha And Beta Receptor Subunit 2	Protein Coding	43.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	12518169 11170061 9563926 (more) 15991303 9195405 14996348 12141824 9783688 17164555
22	EIF2AK2	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2	Protein Coding	42.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	15535414 12210408 17501760 (more) 19642004 15684819 14638359 15850464 10745229 10827164 10915068 11093746 11904369 12225331 14986817 18088246 16156900 12927929 14672617 10669323 12944978 15027699 17597457 11023475 12614464 17845542 15767789
23	CLDN9	Claudin 9	Protein Coding	34.3	GeneCards inferred via : Publications Summaries Pathways & Interactions Functions (show sections)
24	IRF7	Interferon Regulatory Factor 7	Protein Coding	33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	18397234
25	JAK1	Janus Kinase 1	Protein Coding	33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	16623280 17877826
26	STAT1	Signal Transducer And Activator Of Transcription 1	Protein Coding	32.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	14690454 14699505 16162158 (more) 16306605 20014458
27	GGT1	Gamma-Glutamyltransferase 1	Protein Coding	31.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16082285 8808432 15369508 (more) 17032410 10980061 7712308 8628133 9612837 8847041 18166859 7911669 9097279 14502317 10934805 14748879 17845689 15565603 9790451 19690766 12211726
28	SOCS3	Suppressor Of Cytokine Signaling 3	Protein Coding	30.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	16831601 17668875 19803812 (more) 19624774 17881539 16299039 19284081
29	CLEC4M	C-Type Lectin Domain Family 4 Member M	Protein Coding	30.78	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Proteins Functions (show sections)	19785948 12634366 16816373 (more) 15254204 15496474 15371595 17500230
30	TYK2	Tyrosine Kinase 2	Protein Coding	30.34	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)	17877826
31	HM13	Histocompatibility Minor 13	Protein Coding	30.33	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Summaries Functions (show sections)	16227228 19281487 12966028
32	TNF	Tumor Necrosis Factor	Protein Coding	30.11	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Pathways & Interactions (show sections)	20104750 14607710 8591843 (more) 15256977 16955390 20104757 10515837 15638425 11694847 9515764 10959809 11115049 18407594 12533971 15548263 8601375 17052277 16924392 12141823 19469176 11199370 14688215 11830340 9440625 11922568 9021719 10235183 11899822 16425360 14738564 12498809 11455194 11338847 10469062 18069394 14598593 11408015 15807457 18482281 18273504 18372599 16689658 16454849 16408623 16279550 14583571 12653886 20402671 15625348 15286811 15100460 10614716 18190648 18063307 17659726 16979537 16506276 17353164 15362767 15232637 15164510 14687828 12834858 12591081 10389289 18775023 10930306 8666316 19302182 18515332 16323137 15698524 15122751 14988838 14960532 14635012 12949432 11995406 7587825 17003955 15671755 15147353 9781809 9626579 18688917 18585970 17828818 11408014 11196686 20214221 18216180 16764700 12663233 14971716
33	ISG20	Interferon Stimulated Exonuclease Gene 20	Protein Coding	29.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications Functions (show sections)	18338947 17302252 16731032
34	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	29.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18822499 17465499 15192276 (more) 12403355 18760981 17389454 18775023 19195322 9164978 12794718 19918044 16960776 11467655 20186843 16150856 11207658
35	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	29.71	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Proteins Functions (show sections)
36	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	29.69	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)

Sources

Variations for Hepatitis C

Sources

Expression for Hepatitis C

Search GEO for disease gene expression data for Hepatitis C.

Sources

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 25)

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.26	DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
2	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	12.96	DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
3	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.91	IFNA1 IFNA2 IFNAR1 IFNB1 IRF3 TLR3
4	Toll-like Receptor Signaling Pathway ³⁷ ¹ Show member pathways Chagas disease (American trypanosomiasis) ³⁷ NOD-like receptor signaling pathway ³⁷ NOD-like Receptor Signaling Pathways ⁶⁵ Regulation of toll-like receptor signaling pathway ¹	12.89	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG IRF3
5	RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ³⁷ Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of RIG-I/MDA5 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ RIG-I-like Receptor Signaling ¹ RIG-I-like receptor signaling pathway ³⁷ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶ Virus Detection and Induction of Antiviral Signaling Pathways by RIG-I-like Receptors (RLR) ⁶⁵	12.59	DDX58 IFNA1 IFNA2 IFNB1 IFNG IRF3
6	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.5	DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
7	NF-kappaB Signaling ⁴	12.49	DDX58 IFNA1 IFNG IRF3 MAVS TLR3
8	Immune response Role of DAP12 receptors in NK cells ²² Show member pathways Immune response CD16 signaling in NK cells ²² Natural killer cell mediated cytotoxicity ³⁷	12.42	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
9	Interferon gamma signaling ⁶⁶ Show member pathways Interferon Signaling ⁶⁶ Regulation of IFNG signaling ⁶⁶	12.4	DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
10	Cytosolic sensors of pathogen-associated DNA ⁶⁶ Show member pathways DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁶ IkBA variant leads to EDA-ID ⁶⁶ IKBKB deficiency causes SCID ⁶⁶ IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) ⁶⁶ IRF3 mediated activation of type 1 IFN ⁶⁶ IRF3-mediated induction of type I IFN ⁶⁶ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁶ Regulation by TREX1 ⁶⁶ Regulation of innate immune responses to cytosolic DNA ⁶⁶ RIP-mediated NFkB activation via ZBP1 ⁶⁶ STAT6-mediated induction of chemokines ⁶⁶ STING mediated induction of host immune responses ⁶⁶ TAK1 activates NFkB by phosphorylation and activation of IKKs complex ⁶⁶ TRAF6 mediated NF-kB activation ⁶⁶ ZBP1(DAI) mediated induction of type I IFNs ⁶⁶	12.32	DDX58 IRF3 MAVS TLR3
11	JAK-STAT signaling pathway (KEGG) ³⁷ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵	12.3	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
12	Type I Interferon Signaling Pathways ⁶⁵ Show member pathways Inhibition of TSC complex formation by PKB ⁶⁶ Interferon Pathway ⁶⁴ Type II Interferon Signaling Pathways ⁶⁵	12.23	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
13	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶⁴ Interferon alpha/beta signaling ⁶⁶ Regulation of IFNA signaling ⁶⁶	12.2	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG IRF3
14	Tuberculosis ³⁷	12.14	IFNA1 IFNA2 IFNB1 IFNG
15	Necroptosis ³⁷ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.12	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG TLR3
16	Epstein-Barr virus infection ³⁷	12.1	DDX58 IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
17	Factors involved in megakaryocyte development and platelet production ⁶⁶	12.07	IFNA1 IFNA2 IFNB1 IRF3
18	Osteoclast differentiation ³⁷	11.91	IFNAR1 IFNB1 IFNG
19	Jak-Stat Signaling Pathway (sino) ⁶⁷	11.8	IFNA1 IFNA2 IFNAR1 IFNB1 IFNG
20	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.64	IFNA2 IFNB1 IFNG
21	Hepatitis C ³⁷	11.55	CD81 CLDN1 CLDN6 DDX58 IFNA1 IFNA2
22	all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴	11.38	IFNA1 IFNA2 IFNB1
23	Type II interferon signaling (IFNG) ¹	11.3	IFNA2 IFNB1 IFNG
24	Osteoclast Signaling ¹	10.82	IFNAR1 IFNB1
25	Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics ⁶¹ Show member pathways Inhibition of PKR ⁶⁶	10.72	DDX58 IFNA2 IFNAR1 IRF3 MAVS

Sources

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	bicellular tight junction	GO:0005923	9.33	CLDN1 CLDN6 DDX58
2	extracellular space	GO:0005615	9.23	GPT IFNA1 IFNA2 IFNB1 IFNG IFNL4
3	endolysosome membrane	GO:0036020	8.96	LDLR TLR3

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

(show all 42)

#	Name	GO ID	Score	Top Affiliating Genes
1	adaptive immune response	GO:0002250	9.98	IFNA1 IFNA2 IFNB1 IFNG
2	cytokine-mediated signaling pathway	GO:0019221	9.98	IFNA1 IFNA2 IFNAR1 IFNB1
3	cell surface receptor signaling pathway	GO:0007166	9.97	CD81 IFNA2 IFNB1 IFNG
4	defense response	GO:0006952	9.88	IFNA1 IFNA2 IFNB1 TLR3
5	response to virus	GO:0009615	9.85	DDX58 IFNAR1 IFNB1 IFNG TLR3
6	viral entry into host cell	GO:0046718	9.83	CD81 CLDN1 CLDN6 LDLR SCARB1
7	B cell differentiation	GO:0030183	9.82	IFNA1 IFNA2 IFNB1
8	viral process	GO:0016032	9.81	CD81 CLDN1 CLDN6 DDX58 IRF3 KRT18
9	humoral immune response	GO:0006959	9.78	IFNA1 IFNA2 IFNB1 IFNG
10	extrinsic apoptotic signaling pathway	GO:0097191	9.77	IFNG KRT18 TLR3
11	B cell proliferation	GO:0042100	9.74	IFNA1 IFNA2 IFNB1
12	negative regulation of type I interferon production	GO:0032480	9.73	DDX58 IRF3 MAVS
13	positive regulation of interleukin-8 production	GO:0032757	9.72	DDX58 MAVS TLR3
14	type I interferon signaling pathway	GO:0060337	9.72	IFNA1 IFNA2 IFNAR1 IFNB1 IRF3
15	positive regulation of interferon-beta production	GO:0032728	9.71	DDX58 IRF3 MAVS TLR3
16	T cell activation involved in immune response	GO:0002286	9.7	IFNA1 IFNA2 IFNB1
17	calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules	GO:0016338	9.69	CLDN1 CLDN6
18	natural killer cell activation involved in immune response	GO:0002323	9.69	IFNA1 IFNA2 IFNB1
19	cellular response to low-density lipoprotein particle stimulus	GO:0071404	9.68	CD81 LDLR
20	cellular response to interferon-beta	GO:0035458	9.68	IFNB1 TLR3
21	positive regulation of tumor necrosis factor secretion	GO:1904469	9.67	DDX58 MAVS
22	positive regulation of interferon-alpha production	GO:0032727	9.67	DDX58 IRF3 MAVS
23	positive regulation of peptidyl-serine phosphorylation of STAT protein	GO:0033141	9.67	IFNA1 IFNA2 IFNB1 IFNG
24	positive regulation of protein import into nucleus, translocation	GO:0033160	9.66	IFNG MAVS
25	positive regulation of triglyceride biosynthetic process	GO:0010867	9.66	LDLR SCARB1
26	positive regulation of type I interferon-mediated signaling pathway	GO:0060340	9.65	IRF3 MAVS
27	high-density lipoprotein particle clearance	GO:0034384	9.65	LDLR SCARB1
28	positive regulation of interferon-alpha secretion	GO:1902741	9.65	DDX58 MAVS
29	cellular response to dsRNA	GO:0071359	9.63	IRF3 TLR3
30	cholesterol import	GO:0070508	9.63	LDLR SCARB1
31	negative regulation of T cell differentiation	GO:0045581	9.62	IFNA2 IFNB1
32	positive regulation of myeloid dendritic cell cytokine production	GO:0002735	9.62	DDX58 MAVS
33	positive regulation of response to cytokine stimulus	GO:0060760	9.61	DDX58 MAVS
34	detection of virus	GO:0009597	9.61	DDX58 TLR3
35	positive regulation of interferon-beta secretion	GO:0035549	9.6	DDX58 MAVS
36	negative regulation of T-helper 2 cell cytokine production	GO:2000552	9.58	IFNA2 IFNB1
37	cellular response to exogenous dsRNA	GO:0071360	9.56	DDX58 IFNB1 MAVS TLR3
38	regulation of phosphatidylcholine catabolic process	GO:0010899	9.54	LDLR SCARB1
39	response to exogenous dsRNA	GO:0043330	9.43	DDX58 IFNA1 IFNA2 IFNB1 IRF3 TLR3
40	defense response to virus	GO:0051607	9.28	DDX58 IFNA1 IFNA2 IFNB1 IFNG IFNL4
41	innate immune response	GO:0045087	10.06	DDX58 IFNL4 IRF3 MAVS TLR3
42	regulation of signaling receptor activity	GO:0010469	10.04	IFNA1 IFNA2 IFNB1 IFNG IFNL4

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.85	CLDN1 CLDN6 DDX58 IRF3 LDLR TLR3
2	cytokine activity	GO:0005125	9.55	IFNA1 IFNA2 IFNB1 IFNG IFNL4
3	cytokine receptor binding	GO:0005126	9.43	IFNA1 IFNA2 IFNB1
4	low-density lipoprotein particle binding	GO:0030169	9.32	LDLR SCARB1
5	type I interferon receptor binding	GO:0005132	9.13	IFNA1 IFNA2 IFNB1
6	virus receptor activity	GO:0001618	9.02	CD81 CLDN1 CLDN6 LDLR SCARB1

Sources

Sources for Hepatitis C

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris </

Hepatitis C (NANBH)

Aliases & Classifications for Hepatitis C

MalaCards integrated aliases for Hepatitis C:

Classifications:

External Ids:

Summaries for Hepatitis C

Related Diseases for Hepatitis C

Diseases in the Hepatitis family:

Diseases related to Hepatitis C via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Hepatitis C:

Symptoms & Phenotypes for Hepatitis C

Symptoms:

MGI Mouse Phenotypes related to Hepatitis C:

Drugs & Therapeutics for Hepatitis C

FDA approved drugs:

Drugs for Hepatitis C (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cochrane evidence based reviews: hepatitis c

Genetic Tests for Hepatitis C

Anatomical Context for Hepatitis C

MalaCards organs/tissues related to Hepatitis C:

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis C:

Publications for Hepatitis C

Articles related to Hepatitis C:

Genes for Hepatitis C

Genes related to Hepatitis C (1 elite genes):

Variations for Hepatitis C

Expression for Hepatitis C

Pathways for Hepatitis C

Pathways related to Hepatitis C according to GeneCards Suite gene sharing:

GO Terms for Hepatitis C

Cellular components related to Hepatitis C according to GeneCards Suite gene sharing:

Biological processes related to Hepatitis C according to GeneCards Suite gene sharing:

Molecular functions related to Hepatitis C according to GeneCards Suite gene sharing:

Sources for Hepatitis C

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :